Below, we describe the currently known tumor-intrinsic mechanisms of CD19 CAR-T therapy resistance, highlighting the similarities and differences between various B cell malignancies, particularly B-ALL and B cell lymphomas (Figure 1). The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.